EP2863747A1 - Nouveaux dérivés de cabergoline - Google Patents

Nouveaux dérivés de cabergoline

Info

Publication number
EP2863747A1
EP2863747A1 EP20120879191 EP12879191A EP2863747A1 EP 2863747 A1 EP2863747 A1 EP 2863747A1 EP 20120879191 EP20120879191 EP 20120879191 EP 12879191 A EP12879191 A EP 12879191A EP 2863747 A1 EP2863747 A1 EP 2863747A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
substituted
compound
hydrogen
fluorine atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20120879191
Other languages
German (de)
English (en)
Other versions
EP2863747A4 (fr
Inventor
Jian Zhang
Thomas A. Armer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAP Pharmaceuticals Inc
Original Assignee
MAP Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAP Pharmaceuticals Inc filed Critical MAP Pharmaceuticals Inc
Publication of EP2863747A1 publication Critical patent/EP2863747A1/fr
Publication of EP2863747A4 publication Critical patent/EP2863747A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8

Abstract

La présente invention concerne de nouveaux analogues de cabergoline et des compositions associées. Dans d'autres modes de réalisation, la présente invention concerne des méthodes de traitement, de prévention ou d'amélioration d'une variété de troubles médicaux, tels que, par exemple la migraine et la maladie de Parkinson, à l'aide des composés et compositions de la présente invention. Dans encore d'autres modes de réalisation, la présente invention concerne des procédés pour l'agonisation de récepteurs D2 dopaminergiques et/ou l'antagonisation ou l'inhibition de l'activité de récepteurs, tels que les récepteurs 5-HT2 de la sérotonine à l'aide des composés et compositions de la présente invention. Dans encore d'autres modes de réalisation, la présente invention concerne des procédés pour l'agonisation de récepteurs, tels que, par exemple, le récepteur 5-HTID et/ou 5-HTIB, sans l'agonisation (ou une agonisation très faible) du récepteur 5-HT2B, à l'aide des composés et compositions de la présente invention.
EP12879191.0A 2012-06-22 2012-06-22 Nouveaux dérivés de cabergoline Withdrawn EP2863747A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/043687 WO2013191704A1 (fr) 2012-06-22 2012-06-22 Nouveaux dérivés de cabergoline

Publications (2)

Publication Number Publication Date
EP2863747A1 true EP2863747A1 (fr) 2015-04-29
EP2863747A4 EP2863747A4 (fr) 2015-12-23

Family

ID=49769156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12879191.0A Withdrawn EP2863747A4 (fr) 2012-06-22 2012-06-22 Nouveaux dérivés de cabergoline

Country Status (11)

Country Link
EP (1) EP2863747A4 (fr)
JP (1) JP2015525239A (fr)
CN (1) CN104822264A (fr)
AU (1) AU2012382929A1 (fr)
BR (1) BR112014031945A2 (fr)
CA (1) CA2876321A1 (fr)
HK (1) HK1208997A1 (fr)
IL (1) IL236310A0 (fr)
RU (1) RU2014153672A (fr)
SG (1) SG11201408567PA (fr)
WO (1) WO2013191704A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017015487A2 (pt) * 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
CN106866656A (zh) * 2017-02-28 2017-06-20 西南交通大学 一类麦角碱衍生物及其在预防和治疗精神疾病的用途
EP3530651A1 (fr) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Dérivés de l'indole et du benzimidazole comme antagonistes doubles des récepteurs 5-ht2a et 5-ht6

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DK338789A (da) * 1988-07-15 1990-01-16 Schering Ag 2-substituerede ergolinylurinstofderivater og fremgangsmaade til fremstilling deraf, deres anvendelse som laegemidler samt mellemprodukter til fremstilling deraf
DE3913756A1 (de) * 1989-04-21 1990-10-25 Schering Ag 8(beta)-substituierte ergoline, verfahren zu ihrer herstellung und ihre verwendung
EP0664705B1 (fr) * 1993-08-18 2000-10-04 Alcon Laboratories, Inc. Compositions de derives de l'ergoline pour le traitement du glaucome
CZ287176B6 (cs) * 1997-10-03 2000-10-11 Galena A. S. Způsob přípravy ergolinových derivátů
WO2004069252A1 (fr) * 2003-02-05 2004-08-19 Pharmacia Italia Spa Cabergoline utilisee dans le traitement prophylactique de la migraine
GB0307377D0 (en) * 2003-03-31 2003-05-07 Merad Pharmaceuticals Ltd Ergoline derivatives
HUP0400517A3 (en) * 2004-03-04 2006-05-29 Richter Gedeon Vegyeszet Process for producing cabergoline
WO2006097345A1 (fr) * 2005-03-17 2006-09-21 Synthon Argentina S.A. Procede ameliore de preparation de la cabergoline
GB0511060D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP2067780A1 (fr) * 2007-12-07 2009-06-10 Axxonis Pharma AG Dérivés d'ergoline en tant que piégeurs de radicaux sélectifs pour les neurones
CA2749317A1 (fr) * 2009-01-09 2010-07-15 President And Fellows Of Harvard College Composes fluores et leurs procedes d'utilisation
CA2761064A1 (fr) * 2009-04-15 2010-10-21 Astrazeneca Ab Pyrimidines substituees par imidazole utiles dans le traitement de troubles lies a la glycogene synthase kinase 3, tels que la maladie d'alzheimer
EP2793583A4 (fr) * 2011-12-21 2015-08-12 Map Pharmaceuticals Inc Nouveaux composés neuromodulateurs

Also Published As

Publication number Publication date
CA2876321A1 (fr) 2013-12-27
AU2012382929A1 (en) 2015-02-05
SG11201408567PA (en) 2015-02-27
BR112014031945A2 (pt) 2017-06-27
JP2015525239A (ja) 2015-09-03
WO2013191704A1 (fr) 2013-12-27
IL236310A0 (en) 2015-02-26
EP2863747A4 (fr) 2015-12-23
RU2014153672A (ru) 2016-08-10
HK1208997A1 (en) 2016-03-24
CN104822264A (zh) 2015-08-05

Similar Documents

Publication Publication Date Title
US10308651B2 (en) Ergoline compounds and uses thereof
WO2012177962A1 (fr) Nouveaux analogues de fluoro-ergoline
EP2515654A1 (fr) Analogues d'ergoline
WO2014100354A1 (fr) Nouveaux dérivés de méthysergide
US9012640B2 (en) Cabergoline derivatives
WO2013095708A1 (fr) Nouveaux composés neuromodulateurs
US8722699B2 (en) Iso-ergoline derivatives
EP2934529A1 (fr) Nouveaux dérivés d'ergoline et leurs utilisations
AU2016209490B2 (en) Isoergoline compounds and uses thereof
WO2013191704A1 (fr) Nouveaux dérivés de cabergoline

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHANG, JIAN

Inventor name: ARMER, THOMAS, A.

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151125

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/06 20060101ALI20151119BHEP

Ipc: A61K 31/44 20060101AFI20151119BHEP

Ipc: C07D 457/06 20060101ALI20151119BHEP

Ipc: A61P 25/16 20060101ALI20151119BHEP

Ipc: C07D 457/04 20060101ALI20151119BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208997

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160622

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1208997

Country of ref document: HK